3因子前列红素复合度与4因子前列红素复合度用于逆转口服因子XA抑制剂
William Blake Hays1, Kelsey Billups2, Jessica Nicholson3
1Department of Pharmacy, Indiana University Health West Hospital, Avon, IN, USA.
Journal of thrombosis and thrombolysis
|October 29, 2024
概括
四因子前素复合缩物 (4F-PCC) 和三因子PCC (3F-PCC) 在逆转XA因子抑制剂出血方面表现出类似的有效性和安全性. 这项研究发现,两种治疗方法之间的静血疗效或不良事件没有显著差异.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 临床医学 临床医学
背景情况:
- 口服的Xa因子抑制剂 (FXa) 是广泛使用的抗凝剂.
- 与FXa抑制剂相关的出血并发症需要有效的逆转策略.
- 现有的逆转药物包括安德克萨内特阿尔法和4因子前激素复合物缩物 (4F-PCC).
研究的目的:
- 为了比较4F-PCC与3F-PCC的血液静止效果和安全性,在与口服FXa抑制剂相关的大型出血的患者中.
- 评估二次结局,包括血栓栓塞,死亡率和住院时间.
主要方法:
- 一项追溯的多中心研究,涉及成年患者,患有口服FXa抑制剂引起的严重出血.
- 患者接受了4F-PCC (n=64) 或3F-PCC (n=61).
- 评估的结果包括静血疗效,血栓栓塞,住院死亡率和住院时间.
主要成果:
- 整体血静效率为84%,4F-PCC和3F-PCC组之间没有显著差异 (p=0.81).
- 多变量分析,根据基线特征进行调整,证实有效性没有显著差异.
- 在血栓栓塞发生率,住院死亡率或住院时间之间没有发现显著差异.
结论:
- 4F-PCC和3F-PCC似乎在与口服FXa抑制剂相关的大型出血的管理中具有相似的有效性和安全性.
- 这些发现表明,3F-PCC可能是FXa抑制剂相关出血的可行替代品.
- 建议进行进一步的研究,以确认3F-PCC的安全性和有效性.
相关概念视频
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
625
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
625
01:20Extrinsic and Intrinsic Pathways of Hemostasis
5.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.9K